Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;11(1):134-135.
doi: 10.1002/cpdd.1061. Epub 2021 Dec 23.

Subcutaneous Atezolizumab: A Jab Without a Benefit

Cody J Peer  1 , Sara M Zimmerman  1 , William D Figg  1 , Daniel A Goldstein  2   3   4 , Mark J Ratain  5
Affiliations
Comment

Subcutaneous Atezolizumab: A Jab Without a Benefit

Cody J Peer et al. Clin Pharmacol Drug Dev. 2022 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Felip E, Burotto M, Zvirbule Z, et al. Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer. Clin Pharmacol Drug Dev. 2021;10(10):1142-1155.
    1. Goldstein DA, Ratain MJ. Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemother Pharmacol. 2019;84(6):1153-1155.
    1. Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593-603.
    1. FDA. Clinical pharmacology and biopharmaceutics review: appliation number 761034Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034orig1s000c.... Accessed December 9, 2021.
    1. Goldstein DA, Ratain MJ. Safety, clinical activity, and biological correlates of response in patients with metastatic melanoma: results from a phase I trial of atezolizumab [letter]. Clin Cancer Res. 2020;26(10):2435.

LinkOut - more resources